Pediatric methylphenidate exposures: 7-year experience of poison centers in the United States

Area of Science:

• Pediatric Toxicology
• Pharmacovigilance
• Public Health

Background:

• Methylphenidate is a central nervous system stimulant commonly prescribed for Attention Deficit Hyperactivity Disorder (ADHD).
• Understanding exposure trends and toxicity is crucial for pediatric safety and public health.
• National poison center data provides a valuable resource for analyzing drug exposure patterns.

Purpose of the Study:

• To evaluate the trends and toxicity associated with pediatric methylphenidate exposures.
• To analyze the frequency and outcomes of methylphenidate exposures in children and adolescents.
• To correlate exposure trends with the increasing therapeutic use of methylphenidate.

Main Methods:

• Analysis of national poison center data from 1993 to 1999.
• Inclusion of all pediatric methylphenidate exposure cases reported during the study period.
• Categorization of exposure outcomes, reasons for exposure, and patient demographics.

Main Results:

• A significant increase in methylphenidate exposures was observed, from 927 in 1993 to 2,445 in 1999.
• The majority of exposures resulted in no effect (60.3%) or minor effects (28.7%), with no reported fatalities.
• Unintentional errors were common in younger children, while suicide attempts were more frequent in adolescents, who also experienced more severe outcomes and hospitalizations.

Conclusions:

• The rising incidence of methylphenidate exposures reported to poison centers parallels its increased therapeutic application.
• Adolescents represent a higher-risk group for methylphenidate toxicity, necessitating targeted prevention strategies.
• Continued monitoring of methylphenidate exposures is essential to ensure pediatric safety amidst evolving treatment paradigms.